The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 Cases

Imatinib is the treatment of choice for FIP1L1/PDGFRA (F/P)-associated chronic eosinophilic leukemia (F/P(+) CEL), but its optimal dosing, duration, and possibility of discontinuation are still a matter of debate. A retrospective multicenter study was conducted with 44 F/P(+) CEL patients identified...

Descripción completa

Detalles Bibliográficos
Autores principales: Legrand, Fanny, Renneville, Aline, MacIntyre, Elizabeth, Mastrilli, Samuel, Ackermann, Felix, Cayuela, Jean Michel, Rousselot, Philippe, Schmidt-Tanguy, Aline, Fain, Olivier, Michel, Marc, de Jaureguiberry, Jean-Pierre, Hatron, Pierre-Yves, Cony-Makhoul, Pascale, Lefranc, Didier, Sène, Damien, Cottin, Vincent, Hamidou, Mohamed, Lidove, Olivier, Baruchel, André, Dubucquoi, Sylvain, Bletry, Olivier, Preudhomme, Claude, Capron, Monique, Prin, Lionel, Kahn, Jean Emmanuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2013
Materias:
Original Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4553979/
https://www.ncbi.nlm.nih.gov/pubmed/23982058
http://dx.doi.org/10.1097/MD.0b013e3182a71eba

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4553979/
https://www.ncbi.nlm.nih.gov/pubmed/23982058
http://dx.doi.org/10.1097/MD.0b013e3182a71eba

Ejemplares similares